Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight.
Tokuchi Y, Suda G, Kawagishi N, Ohara M, Kohya R, Sasaki T, Yoda T, Maehara O, Ohnishi S, Kubo A, Yoshida S, Fu Q, Yang Z, Hosoda S, Kitagataya T, Suzuki K, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N. Tokuchi Y, et al. Among authors: kawagishi n. Hepatol Res. 2023 Jul;53(7):595-606. doi: 10.1111/hepr.13899. Epub 2023 Apr 4. Hepatol Res. 2023. PMID: 36945790
Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
Kawagishi N, Suda G, Nakamura A, Kimura M, Maehara O, Suzuki K, Nakamura A, Ohara M, Izumi T, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Miyoshi H, Sakamoto N. Kawagishi N, et al. PLoS One. 2018 Dec 21;13(12):e0209615. doi: 10.1371/journal.pone.0209615. eCollection 2018. PLoS One. 2018. PMID: 30576386 Free PMC article.
Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter.
Izumi T, Sho T, Morikawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Umemura M, Shimazaki T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Kudo Y, Nishida M, Ono K, Baba M, Furuya K, Sakamoto N. Izumi T, et al. Among authors: kawagishi n. Hepatol Res. 2019 Oct;49(10):1207-1217. doi: 10.1111/hepr.13391. Epub 2019 Jul 10. Hepatol Res. 2019. PMID: 31219667
Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis.
Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Kimura M, Maehara O, Shimazaki T, Yamamoto K, Shigesawa T, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Suzuki K, et al. Among authors: kawagishi n. Hepatol Res. 2019 Nov;49(11):1294-1304. doi: 10.1111/hepr.13399. Epub 2019 Jul 25. Hepatol Res. 2019. PMID: 31260579
Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs.
Suda G, Kimura M, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Maehara O, Shimazaki T, Morikawa K, Natsuizaka M, Ogawa K, Sakamoto N. Suda G, et al. Among authors: kawagishi n. Hepatol Res. 2019 Nov;49(11):1275-1285. doi: 10.1111/hepr.13401. Epub 2019 Jul 23. Hepatol Res. 2019. PMID: 31261439
High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C.
Kawagishi N, Suda G, Kimura M, Maehara O, Shimazaki T, Yamada R, Kitagataya T, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Sakamoto N. Kawagishi N, et al. Hepatol Res. 2020 Jun;50(6):671-681. doi: 10.1111/hepr.13490. Epub 2020 Feb 18. Hepatol Res. 2020. PMID: 32020702 Free article.
Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting.
Sho T, Suda G, Ogawa K, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Meguro T, Saga A, Miyagishima T, Yokoo H, Kamiyama T, Taketomi A, Sakamoto N. Sho T, et al. Among authors: kawagishi n. JGH Open. 2019 Jun 10;4(1):54-60. doi: 10.1002/jgh3.12209. eCollection 2020 Feb. JGH Open. 2019. PMID: 32055698 Free PMC article.
Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
Kitagataya T, Suda G, Nagashima K, Katsurada T, Yamamoto K, Kimura M, Maehara O, Yamada R, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Komatsu Y, Hata H, Takeuchi S, Abe T, Sakakibara-Konishi J, Teshima T, Homma A, Sakamoto N. Kitagataya T, et al. Among authors: kawagishi n. J Gastroenterol Hepatol. 2020 Oct;35(10):1782-1788. doi: 10.1111/jgh.15041. Epub 2020 Mar 31. J Gastroenterol Hepatol. 2020. PMID: 32187734 Free article.
Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people.
Ohara M, Suda G, Kimura M, Maehara O, Shimazaki T, Shigesawa T, Suzuki K, Nakamura A, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kobayashi T, Uebayashi M, Takagi R, Yokota I, Shimamura T, Sakamoto N. Ohara M, et al. Among authors: kawagishi n. Hepatol Res. 2020 Jun;50(6):715-725. doi: 10.1111/hepr.13499. Epub 2020 Apr 7. Hepatol Res. 2020. PMID: 32202371
203 results